JMJ30 Antibody

What is JMJ30 and why is it significant for plant research?

JMJ30 (also referred to as JMJD5) is a Jumonji C domain-containing protein that plays a crucial role in the Arabidopsis circadian clock. It belongs to the JmjC domain-only group, which consists of four members in Arabidopsis. JMJ30 is significant because it contains the conserved Fe(II)- and α-ketoglutarate-binding amino acids required for histone demethylation, suggesting its function as a histone demethylase . The protein is primarily localized to the nucleus, further supporting its role in chromatin modification . JMJ30 exhibits a robust circadian rhythm of expression with peak levels occurring around dusk (Zeitgeber time ZT-12) under both diurnal and constant white light conditions . This rhythmic expression pattern makes JMJ30 a valuable protein for studying the molecular mechanisms underlying circadian rhythms in plants.

How can I validate the specificity of a JMJ30 antibody?

Validating JMJ30 antibody specificity requires a multi-faceted approach. First, perform Western blot analysis using protein extracts from wild-type plants alongside jmj30 knockout mutants (such as jmj30-1 and jmj30-2). A specific antibody should detect a band of approximately 67 kDa in wild-type samples that is absent in the mutant lines . Second, include JMJ30 overexpression lines (such as 35S:JMJ30-GFP or 35S:JMJ30-HA) as positive controls, which should show enhanced signal intensity at the expected molecular weight . Third, conduct immunoprecipitation followed by mass spectrometry to confirm that the antibody is capturing JMJ30 rather than other Jumonji family proteins. Finally, perform immunolocalization experiments to verify that the antibody detects JMJ30 primarily in the nucleus, consistent with its known subcellular localization . Cross-reactivity with other JmjC domain-containing proteins should be assessed, particularly with the three other members of the JmjC domain-only group.

How should I design a ChIP experiment using JMJ30 antibodies?

Designing a successful Chromatin Immunoprecipitation (ChIP) experiment with JMJ30 antibodies requires careful planning. Based on published research, the following methodology is recommended:

• Sample preparation: Grow Arabidopsis seedlings on 0.5x MS media for 10 days under 12:12 light:dark cycles. Consider time-course experiments, particularly collecting samples at different circadian time points (e.g., ZT-4, ZT-8, ZT-12) to capture the dynamic binding patterns of JMJ30 .

• Fixation and chromatin extraction: Cross-link protein-DNA complexes with 1% formaldehyde for 10 minutes, followed by quenching with glycine. Isolate nuclei and sonicate to obtain chromatin fragments of 200-500 bp.

• Immunoprecipitation: Use at least 4 biological replicates. If using tagged JMJ30 (e.g., JMJ30-HA), anti-HA antibodies have been successfully employed for ChIP . For endogenous JMJ30, use a validated anti-JMJ30 antibody.

• Controls: Include IgG as a negative control, input chromatin as a normalization control, and preferably a jmj30 mutant as a specificity control. For known JMJ30 targets, positive controls can include promoter regions of LBD16 and LBD29, which have been shown to be directly bound by JMJ30 .

• Analysis: Following DNA purification, perform either locus-specific qPCR or genome-wide analysis through ChIP-seq. For qPCR, normalize data to input before presenting relative to controls .

• Expected outcomes: JMJ30 binding varies temporally, with strongest binding observed at 2-4 days after callus induction for targets like LBD16 and LBD29 , or at specific circadian time points for clock-regulated genes.

What controls should be included when performing Western blots for JMJ30 detection?

When performing Western blot analysis to detect JMJ30, the following controls should be included to ensure reliable and interpretable results:

• Positive controls:

  • Protein extracts from plants overexpressing JMJ30 (e.g., 35S:JMJ30-GFP or 35S:JMJ30-HA)

  • Recombinant JMJ30 protein (if available)

• Negative controls:

  • Protein extracts from jmj30 knockout mutants (e.g., jmj30-1, jmj30-2)

  • Pre-immune serum control for antibody specificity

• Loading controls:

  • Anti-histone H3 antibody (ab1791; Abcam) for nuclear proteins

  • Anti-UGPase antibody (AS05086, AgriSera) for total protein normalization

• Technical controls:

  • Molecular weight marker to confirm the expected size of JMJ30 (~67 kDa)

  • Secondary antibody-only control to detect non-specific binding

  • Blocking peptide competition assay to validate antibody specificity

• Experimental validation:

  • Time-course samples to detect circadian oscillation of JMJ30 protein levels (peaks around dusk, ZT-12)

  • Samples from different tissues to assess tissue-specific expression patterns

The recommended protein extraction method involves grinding plant tissue in homogenization buffer (25 mM MOPS (pH 7.8), 0.25 M sucrose, 0.1 mM MgCl₂, Complete EDTA-free protease-inhibitor cocktail) at 4°C, followed by Bradford assay for protein quantification . Typically, 50 μg of protein is sufficient for JMJ30 detection in immunoblot analysis.

How can JMJ30 antibodies be used to study JMJ30's role in histone demethylation?

JMJ30 antibodies can be employed in several complementary approaches to investigate its role in histone demethylation:

• ChIP-seq analysis: Use JMJ30 antibodies to perform ChIP-seq experiments to identify genome-wide binding sites of JMJ30. This can be coupled with ChIP-seq for specific histone methylation marks (H3K36me3, H3K9me3, H3K27me3) in wild-type and jmj30 mutant plants to determine which histone marks are affected by JMJ30 binding .

• Sequential ChIP (Re-ChIP): Perform sequential immunoprecipitation with JMJ30 antibodies followed by antibodies against specific histone methylation marks to identify regions where JMJ30 and particular histone modifications co-occur.

• Immunoblot analysis: Compare the global levels of various histone methylation marks (H3K36me3, H3K9me3, H3K27me3) in wild-type, jmj30 mutant, and JMJ30 overexpression lines using specific antibodies against histone modifications . Research has shown that JMJ30 affects global H3K36me3 levels, as this mark is altered in plants lacking or overexpressing JMJ30 .

• Locus-specific ChIP-qPCR: For known JMJ30 targets (like LBD16 and LBD29), perform ChIP-qPCR using antibodies against specific histone methylation marks to quantify changes in methylation status at these loci in wild-type versus jmj30 mutants. Previous research has shown that H3K9me3 levels at these loci transiently decline during early callus induction in wild-type but not in jmj30-2 mutants .

• In vitro histone demethylation assay: Immunoprecipitate JMJ30 using specific antibodies and test its demethylase activity in vitro using recombinant histones with specific methylation marks, followed by immunoblotting with antibodies against the relevant histone modifications.

The current literature indicates that JMJ30 may function as a histone demethylase affecting H3K9me3 at specific loci and global H3K36me3 levels , although a definitive in vitro histone demethylation assay with JMJ30 would be key to confirming its enzymatic activity .

What are common issues with JMJ30 antibody detection and how can they be resolved?

Researchers often encounter several challenges when working with JMJ30 antibodies. Here are common issues and recommended solutions:

For optimal results when detecting JMJ30, immunoprecipitate the protein using 50 μg of total protein extract before immunoblotting with anti-GFP/HA/specific antibody. ECL Plus reagent (GE Healthcare) has been successfully used for chemiluminescence detection, with BioMax Light Film (Kodak) for image capture . For reproducible results, maintain consistent sample collection times and ensure at least three biological replicates are analyzed.

How can I optimize ChIP protocols specifically for JMJ30 binding studies?

Optimizing ChIP protocols for JMJ30 binding studies requires careful consideration of several factors. Based on published research with JMJ30, the following optimizations are recommended:

• Fixation conditions: Use 1% formaldehyde for crosslinking, but limit fixation time to 10 minutes to avoid overfixation. For studying JMJ30 interactions with histone modifications, consider dual crosslinking with DSG (disuccinimidyl glutarate) followed by formaldehyde.

• Chromatin shearing: Optimize sonication conditions to generate DNA fragments averaging 200-300 bp. For JMJ30 binding sites, such as promoter regions of LBD16 and LBD29, smaller fragments improve resolution .

• Antibody selection and validation: For tagged JMJ30 (JMJ30-HA, JMJ30-GFP), use high-affinity commercial antibodies (anti-HA (ab290; abcam), anti-GFP) . For native JMJ30, ensure the antibody recognizes a region that is accessible when JMJ30 is bound to chromatin.

• Wash stringency: Adjust wash buffer salt concentration based on antibody specificity. Higher stringency (higher salt) reduces background but may reduce recovery of genuine targets.

• Sequential ChIP: To study JMJ30 co-occupancy with specific histone marks, perform sequential ChIP first with JMJ30 antibody followed by antibodies against histone modifications (H3K9me3, H3K36me3) .

• Time-point consideration: JMJ30 binding is dynamic and can vary based on circadian time and developmental stage. For circadian studies, collect samples at 4-hour intervals over a 24-hour period . For developmental studies, focus on key timepoints such as 2-4 days after callus induction, when JMJ30 shows maximal binding to target promoters .

• Controls: Include mock immunoprecipitation (IgG), input control, and chromatin from jmj30 mutants as a specificity control. For known JMJ30 targets, design primers for positive control regions (LBD16/LBD29 promoters) and negative control regions (gene bodies or non-bound promoters) .

• qPCR analysis: Normalize ChIP-qPCR data first to input samples, then present relative to appropriate controls. Include at least four biological replicates for statistical robustness .

What methods can be used to study the interaction between JMJ30 and its protein partners?

JMJ30 interacts with various proteins to perform its functions in chromatin modification and transcriptional regulation. Several methodologies have been successfully employed to study these interactions:

• Yeast Two-Hybrid (Y2H) assays: This approach has been used to demonstrate interactions between JMJ30 and proteins like ATXR2. The methodology involves fusing JMJ30 with the GAL4 activation domain (AD) and potential interacting partners with the DNA-binding domain (BD), followed by assessment of interaction through growth on selective media (-LWHA) .

• Bimolecular Fluorescence Complementation (BiFC): This method allows visualization of protein interactions in plant cells. JMJ30-cYFP and potential interactor-nYFP fusion constructs are transiently co-expressed in Arabidopsis protoplasts, with interaction detected through reconstituted YFP fluorescence. This technique has successfully visualized JMJ30-ATXR2 interactions .

• Co-immunoprecipitation (Co-IP): For this method, plant tissues expressing tagged versions of JMJ30 (e.g., JMJ30-MYC) and its potential interactors (e.g., ATXR2-GFP) are used. Protein complexes are immunoprecipitated with antibodies against one tag and then probed for the presence of the interaction partner using antibodies against the other tag .

• Chromatin Immunoprecipitation followed by mass spectrometry (ChIP-MS): This technique identifies proteins that co-occupy chromatin with JMJ30. After ChIP with JMJ30 antibodies, associated proteins are identified by mass spectrometry.

• GST pull-down assays: This in vitro technique uses recombinant GST-tagged JMJ30 protein immobilized on glutathione-sepharose beads to capture interacting partners from plant extracts, followed by immunoblotting with specific antibodies.

• Proximity-dependent biotin identification (BioID): By fusing JMJ30 to a biotin ligase, proteins in close proximity to JMJ30 in vivo can be biotinylated, captured with streptavidin, and identified by mass spectrometry.

Research has demonstrated that JMJ30 physically associates with ARF7 and ARF19 transcription factors, which bind to LBD promoters, as well as with the histone methyltransferase ATXR2 . These interactions are crucial for understanding how JMJ30 is recruited to specific genomic loci and how it coordinates with other chromatin modifiers to regulate gene expression.

How can JMJ30 antibodies be used to investigate the temporal dynamics of JMJ30 function in the circadian clock?

Investigating the temporal dynamics of JMJ30 function in circadian regulation requires sophisticated experimental approaches using JMJ30 antibodies:

• Time-resolved ChIP-seq: Perform ChIP-seq with JMJ30 antibodies at multiple time points across a circadian cycle (e.g., every 4 hours over 24-48 hours under constant light conditions). This approach reveals how JMJ30 binding to target genes changes over time and correlates with its expression pattern, which peaks around dusk (ZT-12) . Coupled with RNA-seq, this can reveal the relationship between JMJ30 binding and rhythmic gene expression.

• Circadian protein profiling: Use JMJ30 antibodies for immunoblotting of protein samples collected at regular intervals throughout the circadian cycle. This technique has revealed that JMJ30 protein levels oscillate with a circadian rhythm, peaking at dusk . Comparing protein levels with transcript levels (via qRT-PCR) can uncover post-transcriptional regulation of JMJ30.

• Sequential ChIP for temporal changes in histone modifications: Perform sequential ChIP with JMJ30 antibodies followed by antibodies against histone modifications (H3K9me3, H3K36me3) at different circadian time points. This approach can determine when JMJ30's histone demethylase activity is most active during the circadian cycle.

• Circadian phase-specific protein interactions: Use co-immunoprecipitation with JMJ30 antibodies at different circadian phases to identify time-specific protein interactions that may modulate JMJ30 function or localization. For instance, JMJ30's interaction with CCA1 and LHY (which negatively regulate JMJ30 expression) might be phase-dependent .

• Temperature-dependent JMJ30 activity: Since JMJ30/JMJD5 contributes to temperature compensation in the circadian clock , use JMJ30 antibodies to investigate how temperature affects JMJ30 binding, activity, or protein interactions across the temperature range of 12-27°C.

Research has shown that JMJ30 expression is under circadian control and is negatively regulated by CCA1 and LHY, which bind directly to Evening Elements in the JMJ30 promoter . The temporal dynamics of JMJ30 binding to its target genes are therefore likely influenced by its own circadian expression pattern, making time-resolved approaches essential for understanding its function in the clock.

What approaches can be used to differentiate between the epigenetic functions of JMJ30 and other JmjC domain proteins?

Distinguishing the specific functions of JMJ30 from other JmjC domain proteins requires sophisticated experimental approaches that exploit unique features of JMJ30:

• Substrate specificity analysis: Use in vitro histone demethylation assays with immunoprecipitated JMJ30 (using specific antibodies) to determine its preferential histone mark substrates. Compare these with other JmjC proteins to identify unique substrate preferences. Current research suggests JMJ30 may affect H3K9me3 at specific loci and global H3K36me3 levels .

• Genome-wide binding profile comparison: Perform comparative ChIP-seq analysis using antibodies specific to different JmjC proteins (including JMJ30) to identify unique and overlapping binding sites. This approach reveals distinct genomic targets for each protein family member.

• Higher-order mutant analysis: Generate double, triple, or quadruple mutants of JMJ30 with other JmjC domain proteins, particularly those in the same JmjC domain-only group . Use JMJ30 antibodies in ChIP-qPCR and immunoblotting to assess how the loss of multiple JmjC proteins affects histone methylation patterns and target gene expression.

• Temporal and spatial expression analysis: Use JMJ30 antibodies in tissue-specific and time-resolved immunoblotting to compare expression patterns with other JmjC proteins. JMJ30's robust circadian oscillation pattern (peaking at dusk) distinguishes it from many other JmjC proteins that lack strong circadian rhythmicity .

• Protein complex purification: Use JMJ30 antibodies for immunoprecipitation followed by mass spectrometry to identify JMJ30-specific protein complexes that differ from those formed by other JmjC proteins. JMJ30's interactions with ARF7/ARF19 and ATXR2 may be unique to this family member .

• Domain-specific functional analysis: Generate chimeric proteins by swapping domains between JMJ30 and other JmjC proteins, followed by functional complementation assays in jmj30 mutants. Use JMJ30 antibodies to verify expression and localization of these chimeric proteins.

The existing research shows that among the 21 JmjC domain-containing proteins in Arabidopsis, JMJ30 is the only one that shows a robust circadian rhythm of expression . This unique temporal regulation may underpin functional specificity despite structural similarities with other family members.

How can advanced ChIP approaches with JMJ30 antibodies elucidate the relationship between JMJ30 and transcription factors?

Advanced ChIP methodologies using JMJ30 antibodies can reveal the complex interplay between JMJ30 and transcription factors:

• Sequential ChIP (Re-ChIP): This approach can determine if JMJ30 and specific transcription factors (like ARF7/ARF19) co-occupy the same genomic regions simultaneously. First perform ChIP with JMJ30 antibodies, then re-immunoprecipitate the eluate with antibodies against transcription factors . Applied to LBD16 and LBD29 promoters, this technique has shown that JMJ30 and ARF transcription factors co-occupy these regulatory regions.

• ChIP-seq followed by motif analysis: Perform genome-wide ChIP-seq with JMJ30 antibodies and analyze enriched regions for transcription factor binding motifs. This approach has identified Evening Elements (bound by CCA1/LHY) in JMJ30 target genes, providing insight into the reciprocal regulation between JMJ30 and clock components .

• Inducible systems and time-course ChIP: Use plant lines with inducible transcription factor expression (e.g., estradiol-inducible ARF7) and perform time-course ChIP with JMJ30 antibodies after induction. This reveals the temporal order of recruitment between JMJ30 and transcription factors, addressing whether transcription factors recruit JMJ30 or vice versa.

• ChIP-qPCR in transcription factor mutants: Perform ChIP with JMJ30 antibodies in wild-type versus transcription factor mutant backgrounds (e.g., arf7/arf19). If JMJ30 binding is reduced in the mutant, it suggests the transcription factor is required for JMJ30 recruitment. This approach has shown that JMJ30 binding to LBD promoters may depend on ARF transcription factors .

• Mass spectrometry of ChIP samples (ChIP-MS): Immunoprecipitate chromatin with JMJ30 antibodies and identify co-purifying proteins by mass spectrometry. This unbiased approach can identify novel transcription factors that interact with JMJ30 at chromatin.

• Integration with accessible chromatin data: Combine JMJ30 ChIP-seq with ATAC-seq or DNase-seq data to determine if JMJ30 preferentially binds to accessible chromatin regions where transcription factors typically bind.

Research has established that JMJ30 is a direct target of the transcription factors CCA1 and LHY, which bind to Evening Elements in the JMJ30 promoter to repress its expression . Conversely, JMJ30 interacts with ARF transcription factors to modulate the expression of their target genes . These reciprocal relationships demonstrate the complex integration of JMJ30 within transcriptional regulatory networks.